Cargando…

Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model

SIMPLE SUMMARY: Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality in females, with chemotherapy currently the only adjunctive therapy. However, the disadvantages of chemotherapy are represented by toxicity/side effects, and for many women the benefit is un...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihai, Cosmin-Teodor, Mihaila, Ilarion, Pasare, Maria Antoanela, Pintilie, Robert Mihai, Ciorpac, Mitica, Topala, Ionut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164030/
https://www.ncbi.nlm.nih.gov/pubmed/35678664
http://dx.doi.org/10.3390/cimb44050135
_version_ 1784720047214690304
author Mihai, Cosmin-Teodor
Mihaila, Ilarion
Pasare, Maria Antoanela
Pintilie, Robert Mihai
Ciorpac, Mitica
Topala, Ionut
author_facet Mihai, Cosmin-Teodor
Mihaila, Ilarion
Pasare, Maria Antoanela
Pintilie, Robert Mihai
Ciorpac, Mitica
Topala, Ionut
author_sort Mihai, Cosmin-Teodor
collection PubMed
description SIMPLE SUMMARY: Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality in females, with chemotherapy currently the only adjunctive therapy. However, the disadvantages of chemotherapy are represented by toxicity/side effects, and for many women the benefit is uncertain. Cold atmospheric plasma in in vitro and in vivo experiments proved that it is able to selectively inhibit the growth of cancer cells in various cancer types, with less deleterious side effects. Current guidelines include paclitaxel as a chemotherapy of choice for various types of breast cancers. The aim of the study was to evaluate in vitro, on human breast cancer cell lines, a plasma-activated media as a cytotoxic agent and as an associative agent in a combined treatment for breast cancer with paclitaxel. The collected data indicated that the plasma-activated media amplified the cytotoxic effect of paclitaxel. ABSTRACT: The use of plasma-activated media (PAM), an alternative to direct delivery of cold atmospheric plasma to cancer cells, has recently gained interest in the plasma medicine field. Paclitaxel (PTX) is used as a chemotherapy of choice for various types of breast cancers, which is the leading cause of mortality in females due to cancer. In this study, we evaluated an alternative way to improve anti-cancerous efficiency of PTX by association with PAM, the ultimate achievement being a better outcome in killing tumoral cells at smaller doses of PTX. MCF-7 and MDA-MB-231 cell lines were used, and the outcome was measured by cell viability (MTT assay), the survival rate (clonogenic assay), apoptosis occurrence, and genotoxicity (COMET assay). Treatment consisted of the use of PAM in combination with under IC50 doses of PTX in short- and long-term models. The experimental data showed that PAM had the capacity to improve PTX’s cytotoxicity, as viability of the breast cancer cells dropped, an effect maintained in long-term experiments. A higher frequency of apoptotic, dead cells, and DNA fragmentation was registered in cells treated with the combined treatment as compared with those treated only with PT. Overall, PAM had the capacity to amplify the anti-cancerous effect of PTX.
format Online
Article
Text
id pubmed-9164030
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91640302022-06-04 Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model Mihai, Cosmin-Teodor Mihaila, Ilarion Pasare, Maria Antoanela Pintilie, Robert Mihai Ciorpac, Mitica Topala, Ionut Curr Issues Mol Biol Article SIMPLE SUMMARY: Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality in females, with chemotherapy currently the only adjunctive therapy. However, the disadvantages of chemotherapy are represented by toxicity/side effects, and for many women the benefit is uncertain. Cold atmospheric plasma in in vitro and in vivo experiments proved that it is able to selectively inhibit the growth of cancer cells in various cancer types, with less deleterious side effects. Current guidelines include paclitaxel as a chemotherapy of choice for various types of breast cancers. The aim of the study was to evaluate in vitro, on human breast cancer cell lines, a plasma-activated media as a cytotoxic agent and as an associative agent in a combined treatment for breast cancer with paclitaxel. The collected data indicated that the plasma-activated media amplified the cytotoxic effect of paclitaxel. ABSTRACT: The use of plasma-activated media (PAM), an alternative to direct delivery of cold atmospheric plasma to cancer cells, has recently gained interest in the plasma medicine field. Paclitaxel (PTX) is used as a chemotherapy of choice for various types of breast cancers, which is the leading cause of mortality in females due to cancer. In this study, we evaluated an alternative way to improve anti-cancerous efficiency of PTX by association with PAM, the ultimate achievement being a better outcome in killing tumoral cells at smaller doses of PTX. MCF-7 and MDA-MB-231 cell lines were used, and the outcome was measured by cell viability (MTT assay), the survival rate (clonogenic assay), apoptosis occurrence, and genotoxicity (COMET assay). Treatment consisted of the use of PAM in combination with under IC50 doses of PTX in short- and long-term models. The experimental data showed that PAM had the capacity to improve PTX’s cytotoxicity, as viability of the breast cancer cells dropped, an effect maintained in long-term experiments. A higher frequency of apoptotic, dead cells, and DNA fragmentation was registered in cells treated with the combined treatment as compared with those treated only with PT. Overall, PAM had the capacity to amplify the anti-cancerous effect of PTX. MDPI 2022-04-30 /pmc/articles/PMC9164030/ /pubmed/35678664 http://dx.doi.org/10.3390/cimb44050135 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mihai, Cosmin-Teodor
Mihaila, Ilarion
Pasare, Maria Antoanela
Pintilie, Robert Mihai
Ciorpac, Mitica
Topala, Ionut
Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model
title Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model
title_full Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model
title_fullStr Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model
title_full_unstemmed Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model
title_short Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model
title_sort cold atmospheric plasma-activated media improve paclitaxel efficacy on breast cancer cells in a combined treatment model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164030/
https://www.ncbi.nlm.nih.gov/pubmed/35678664
http://dx.doi.org/10.3390/cimb44050135
work_keys_str_mv AT mihaicosminteodor coldatmosphericplasmaactivatedmediaimprovepaclitaxelefficacyonbreastcancercellsinacombinedtreatmentmodel
AT mihailailarion coldatmosphericplasmaactivatedmediaimprovepaclitaxelefficacyonbreastcancercellsinacombinedtreatmentmodel
AT pasaremariaantoanela coldatmosphericplasmaactivatedmediaimprovepaclitaxelefficacyonbreastcancercellsinacombinedtreatmentmodel
AT pintilierobertmihai coldatmosphericplasmaactivatedmediaimprovepaclitaxelefficacyonbreastcancercellsinacombinedtreatmentmodel
AT ciorpacmitica coldatmosphericplasmaactivatedmediaimprovepaclitaxelefficacyonbreastcancercellsinacombinedtreatmentmodel
AT topalaionut coldatmosphericplasmaactivatedmediaimprovepaclitaxelefficacyonbreastcancercellsinacombinedtreatmentmodel